Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The RET gene in thyroid pathology]

F M Michiels1, M Billaud

  • 1Laboratoire de Génétique Oncologique, UMR 1599 CNRS, Institut Gustave Roussy, Villejuif, France.

Archives D'Anatomie Et De Cytologie Pathologiques
|October 1, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties.

Oncogene·2014
Same author

Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1.

Oncogene·2011
Same author

Interaction between nitric oxide signaling and gap junctions: effects on vascular function.

Biochimica et biophysica acta·2011
Same author

The RET receptor: function in development and dysfunction in congenital malformation.

Trends in genetics : TIG·2001
Same author

Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Molecular and cellular biology·2001
Same author

The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret.

Oncogene·2001
Same journal

[Peritoneal pseudomyxoma associated with an ovarian and appendicular mucinous tumor].

Archives d'anatomie et de cytologie pathologiques·1999
Same journal

[Papillary fibroelastoma: a cardiac tumor rarely reported in children].

Archives d'anatomie et de cytologie pathologiques·1999
Same journal

[Extramembranous glomerulonephritis: clinicopathologic finding in a group of 45 Cameroonians].

Archives d'anatomie et de cytologie pathologiques·1999
Same journal

[Biotin-rich pseudoherpetic intranuclear inclusions. A diagnostic pitfall].

Archives d'anatomie et de cytologie pathologiques·1999
Same journal

[Primary gastric MALT lymphoma in children. Report of 2 cases].

Archives d'anatomie et de cytologie pathologiques·1999
Same journal

[Granular cell tumor and congenital epulis. Histochemical and immunohistochemical of 58 cases].

Archives d'anatomie et de cytologie pathologiques·1999
See all related articles

RET gene mutations are key in papillary and medullary thyroid cancers. A new mouse model mimics hereditary MTC, aiding research into RET tyrosine kinase function and thyroid cancer development.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • The RET proto-oncogene encodes a receptor tyrosine kinase vital for embryonic development.
  • Somatic RET gene rearrangements are implicated in papillary thyroid carcinoma (PTC).
  • Germline RET mutations cause multiple endocrine neoplasia type 2 (MEN 2), a hereditary cancer syndrome affecting C-cells.

Purpose of the Study:

  • To review the role of RET mutations in the pathogenesis of PTC and medullary thyroid carcinoma (MTC).
  • To summarize the functional consequences of RET alterations on tyrosine kinase activity.
  • To describe a transgenic mouse model for hereditary MTC.

Main Methods:

  • Review of existing literature on RET gene mutations in thyroid cancer.
  • Analysis of the functional impact of RET mutations on tyrosine kinase activity.

Related Experiment Videos

  • Description of a transgenic mouse model carrying a MEN 2A allele of RET.

    • Main Results:

    • RET gene alterations are crucial in the development of both PTC and MTC.
    • Specific RET mutations affect tyrosine kinase function, contributing to cancer pathogenesis.
    • The described mouse model develops MTC similar to human hereditary MTC.

    Conclusions:

    • RET mutations are central to the development of thyroid cancers, including PTC and hereditary MTC.
    • Understanding RET kinase function is critical for developing targeted therapies.
    • The transgenic mouse model provides a valuable tool for studying MTC and testing therapeutic strategies.